ECR 2013 – Final Programme - myESR.org

Scientific Sessions11:42B-0060 The potential benefit of abdominal CT to helpdifferentiate between strains of clostridium difficileS.N. Reddy, S. Taori, I.R. Poxton, F. Ewing, D. Brown, J.T. Murchison;Edinburgh/UK10:30–12:00 Room F1Oncologic ImagingSS 116 Perfusion CT and MRI: ready for clinicalpracticeModerators: S. Delorme; Heidelberg/DE, F.A. Gallagher; Cambridge/UK10:30B-0061 Functional MRI changes in follow-up after externalbeam radiation therapy of the prostateA.M. Weidner; Mannheim/DE10:39B-0062 Acute changes in rectal cancer perfusion CTparameters during short-course radiotherapy correlatewith radiological response to therapyJ.M. Franklin, E.J. Hill, T. Pwint, F.V. Gleeson, R.A. Sharma, E.M. Anderson;Oxford/UK10:48B-0063 CT perfusion for evaluation of earlytreatment response of liver metastases after90Y-radioembolisationC.S. Reiner, F. Morsbach, B.-R. Sah, N. Schäfer, T. Pfammatter, H. Alkadhi;Zurich/CH10:57B-0064 First-pass perfusion CT on 256-detector row CT in thequantitative assessment of perfusion map for solidmalignant neoplastic liver lesions: preliminary resultsO. Minutolo, D. Ippolito, A.C. Cadonici, P.A. Bonaffini, C.R.G.L. Talei Franzesi,S. Sironi; Monza/IT11:06B-0065 CT perfusion imaging in stage II-III non-small celllung cancer patients undergoing chemo-radiotherapyevaluationof metabolic tumour activityM. Das, B. Reymen, P. Lambin, H. Sharifi, J.E. Wildberger, D. De Ruysscher,W. van Elmpt; Maastricht/NL11:15B-0066 Imaging of antivascular effects of multikinaseinhibitors (MKI) in patients with metastatic renal cellcancer (mRCC) using dynamic contrast- enhanced CT(DCE-CT, perfusion CT): a pilot studyA. Sterzik, M. Staehler, J. Casuscelli, M. Karpitschka, F. Schwarz, M.F. Reiser,A. Graser; Munich/DE11:24B-0067 Early vs late recurrent glioblastomas: added value ofT1-weighted perfusion MR imaging compared with T2-weighted perfusion MR imagingS.J. Kang, H.S. Kim, S.J. Kim, C.G. Choi; Seoul/KR11:33B-0068 Monitoring the antivascular effects of a novelmultimodal therapy with dynamic contrast-enhancedMRI (DCE-MRI) in an experimental human squamouscell carcinoma modelA. Sterzik, P. Paprottka, P. Zengel, S. Roßpunkt, E. Baloch, M. Moser,M.F. Reiser, K. Nikolaou, C. Cyran; Munich/DE11:42B-0069 Fractional 3D quantification of early contrastenhancingtumour fractions on dynamic MRIacquisitions in soft tissue sarcoma: prospectivecomparison with partial tissue-stained pathologicaltumour viability estimatesA.K. Singh, W. Cai, A. Imanzadeh, S. Saini, G. Harris; Boston, MA/US11:51B-0070 A perfusion CT-derived patient-specific arterial inputfunction for pharmacokinetic modelling of dynamiccontrast-enhanced MRIJ.M. Franklin, M. Enescu, E.J. Hill, R.A. Sharma, J.A. Schnabel, F.V. Gleeson,E.M. Anderson; Oxford/UK10:30–12:00 Room F2BreastSS 102Breast MRI: improving accuracy andtissue characterisationModerators: R. Schulz-Wendtland; Erlangen/DE, M. Telesca; Rome/IT10:30B-0071 BI-RADS®-adapted combined contrast-enhancedmagnetic resonance and diffusion-weighted imagingreading for multiparametric imaging of breast lesionsat 3T improves diagnostic accuracyK. Pinker-Domenig, H. Bickel, T.H. Helbich, S. Gruber, S. Trattnig, W. Bogner;Vienna/AT10:39B-0072 The additional value of expert reading of 3 Teslabreast MRI in patients with microcalcifications onmammographyL.G. Merckel 1 , H.M. Verkooijen 1 , N.H.G.M. Peters 1 , R.M. Mann 2 , W.B. Veldhuis 1 ,K.M. Duvivier 1 , T. van Dalen 1 , P.H.M. Peeters 1 , M.A.A.J. van den Bosch 1 ;1Utrecht/NL, 2 Nijmegen/NL10:48B-0073 Which threshold level is appropriate for analysisof the computer-aided detection system of breastMRI? Effect of pathologic tumour characteristics andbiological markersS. Song 1 , B. Seo 1 , K.-W. Hwang 2 , K. Cho 3 , O. Woo 3 ; 1 Ansan/KR, 2 Incheon/KR,3Seoul/KR10:57B-0074 The additional value of diffusion-weighted imaging(DWI) in MR-mammography: should we still look atcurves?P.A.T. Baltzer 1 , M. Dietzel 2 , J.L. Halder 3 , W.A. Kaiser 3 ; 1 Vienna/AT, 2 Erlangen/DE,3Jena/DE11:06B-0075 Apparent diffusion coefficient (ADC) measurementsof breast lesions: most suspect area versus completelesion assessmentP.A.T. Baltzer 1 , M. Dietzel 2 , J.L. Halder 3 , W.A. Kaiser 3 ; 1 Vienna/AT, 2 Erlangen/DE,3Jena/DE11:15B-0076 Combined contrast-enhanced MRI (CE-MRI) and 3Dmultivoxel proton magnetic resonance spectroscopy(3D-1H-MRSI) at 3 Tesla enables an improvedcharacterization of breast tumoursK. Pinker-Domenig, S. Gruber, W. Bogner, B. Brück, H. Bickel, P.A.T. Baltzer,T. Helbich; Vienna/ATB-0060 – B-0076Thursday217